RNF112

Across TCGA pan-cancer cohorts, RNF112 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RNF112 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNF112 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNF112 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

CHOL, HNSC, and PRAD are the cancer types where RNF112 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
HNSC	OS	Median	All	0.139	0.685	.003	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.252	0.700	<.001	6	view →
STAD	DFS	Median	All	1.000	0.334	.027	4	view →
LGG	OS	Median	All	0.307	0.799	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNF112–CHOL (DFS)

Open the CHOL breakdown →